article thumbnail

The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. All rights reserved.

article thumbnail

India’s Growing Importance in Generic Drug API Manufacturing

Drug Patent Watch

“India sometimes describes itself as the ‘pharmacy to the world’ because it is a significant global supplier of affordable therapeutics, including many life-saving medicines for chronic conditions.” India’s Unique Opportunity and Important Responsibility as “Pharmacy to the World.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

He holds a PhD in pharmacy from the University of North Carolina at Chapel Hill, and an MBA from the Rochester Institute of Technology. 2024 Dec 26; Available from: [link] Geukes Foppen RJ, Gioia V, Velez CN. Connect on LinkedIn >> Literature Geukes Foppen RJ, Gioia V, Zoccoli A, Velez CN. Lifescienceleader.com.

Drugs 65
article thumbnail

White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill (rerun)

Drug Channels

Click here to see the original post from September 2024. Below, I review the latest data on 2024 trends and compare them to the pre-pandemic figures. However, provider pushback has limited specialty pharmacies' share gains, so that buy-and-bill remains the most common channel for these products. drug channels.

article thumbnail

Vamorolone

New Drug Approvals

Syn EuropeanJournalofMedicinalChemistry265(2024)116124 Vamorolone (Agamree) On October 26, 2023, Vamorolone, developed jointly by Santhera Pharmaceuticals and ReveraGen BioPharma, has received FDA approval to treat DMD in patients aged 2 years and older [1]. Drugs 2024, 84, 111− 117. (71) 16 February 2024. 70) Keam, S.

FDA 62
article thumbnail

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns

Drug Channels

For 2024, average brand-name drugs list prices grew by only 2.3%. Employers, health plans, and pharmacy benefit managers (PBMs) determine the extent to which patients with insurance share in this ongoing deflation. It's time for Drug Channels annual examination of U.S. brand-name drug pricing.

article thumbnail

Syringe services for people who inject drugs are enormously effective, but remain underused

National Institute on Drug Abuse: Nora's Blog

17 In another study, people who received syringes from an SSP were half as likely to dispose of them improperly compared to people who got them from other sources such as pharmacies. 2024 Feb 23;21(1):50. 2010 Oct 8; accessed on November 13, 2024: apo-nid22857.pdf A recent study analyzing crime reports in an undisclosed U.S.

Drugs 119